Pop-Up Mpox Vaccine Clinic

MAX is working with Ottawa Public Health to host two pop-up immunization clinics for mpox. The clinics are open to members of our community who meet the eligibility criteria and who have not had two doses of the vaccine yet.

Vaccines for HPV and Hepatitis A and B will also be available for those who are eligible. More information for these can be found below and in the Publicly Funded Immunization Schedule for Ontario.

Please take a minute to review the criteria (below) before booking an appointment.

Pop-Up Mpox Vaccine Clinic

Wednesday, July 16 and Wednesday, August 13, 2025
4:00 to 7:00PM
MAX Ottawa Office
400 Cooper St., Suite 9004

calendar.google.com/calendar/u/0/appointments/AcZssZ296RLzCz9yxa3_19Sjd_2Nt5uwkIBB39QcHoY=

If you have questions, please email us at info [at] maxottawa [dot] ca.

Mpox Vaccine and Eligibility

Who can receive the Imvamune® vaccine for protection before an exposure to the mpox virus? 

Anyone who received one dose of the Imvamune® mpox vaccine can now receive a second dose at least 28 days after receiving their first dose. This includes individuals who received the vaccine for protection before or after an exposure to the mpox virus. 

Based on the Ontario Ministry of Health guidelines, the following groups are eligible for a 2-dose series of the Imvamune® vaccine for protection.

a) Two-spirited, non-binary, transgender, cisgender, intersex, or gender-queer individuals who self-identify or have sexual partners who self-identify as belonging to the gay, bisexual, pansexual and other men who have sex with men (gbMSM)
community AND at least one of the following:

• Had a confirmed sexually transmitted infection within the last year.
• Have or are planning to have two or more sexual partners or are in a relationship where at least one of the partners may have other sexual partners.
• Have attended venues for sexual contact (i.e., bath houses, sex clubs) recently or may be planning to, or who work/volunteer in these settings.
• Have had anonymous sex (e.g., using hookup apps) recently or may be planning to.
• Are a sexual contact of an individual who engages in sex work.

b) Individuals who self-identify as engaging in sex work or are planning to, regardless of self-identified sex or gender.

c) Household and/or sexual contacts of those identified for pre-exposure vaccination eligibility in parts (a) and/or (b) above AND who are moderately to severely immunocompromised or pregnant may be considered for pre-exposure vaccination. These individuals may be at higher risk for severe illness from a mpox infection and should contact their healthcare provider or Ottawa Public Health at 613-580-6744 for more information. 

For more information:

ottawapublichealth.ca/en/public-health-topics/monkeypox-virus.aspx

gmsh.ca/mpox

Human Papillomavirus (HPV) Vaccine and Eligibility

The HPV is publicly funded for males aged 9 to 26 in Ontario and is recommended for men who have sex with men. The 9vHPV vaccine is recommended as it provides protection against the greatest number of HPV types and associated diseases like anogenital warts and anal and throat cancers.

The 9vHPV vaccine is approved in Canada for individuals aged 9 to 45 years, but there is no actual upper age limit to receive this vaccine. It’s best to be vaccinated at a younger age before exposure to HPV. Anyone who is sexually active may contract HPV infections, regardless of their sex, gender identity or sexual orientation. People who have received an HPV vaccine are at much lower risk of HPV infections and associated cancers.

The 9vHPV vaccine provides protection against 7 high-risk HPV types, accounting for 90% of all cervical cancers and many anal and throat cancers. This vaccine also protects against 2 low-risk HPV types, which:

• cause about 90% of anogenital warts (relating to the anus and genitals)
• can cause a rare but serious condition where warts develop on the respiratory tract

For more information:

ottawapublichealth.ca/en/public-health-topics/human-papillomavirus-hpv-and-hpv-vaccine.aspx

canada.ca/en/public-health/services/diseases/human-papillomavirus-hpv/spread-prevention-risks.html

Hepatitis A (HA) Vaccine and Eligibility

Pre-exposure HA immunization is at least 90% to 97% effective. Primary immunization is achieved after one dose with a booster dose given 6 to 36 months later, depending on the product.

With few exceptions, people with indications for both the hepatitis A (HA) and hepatitis B (HB) vaccine should be immunized with combined the HAHB vaccine. The HA vaccine can also be administered concomitantly with other vaccines.

Priority populations to receive the vaccine include:

• People use use drugs intravenously
• People with liver disease (chronic), including hepatitis B and C
• Men who have sex with men

For more information:

canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-6-hepatitis-a-vaccine.html

Hepatitis B (HB) Vaccine and Eligibility

HB vaccine is 95% to 100% effective pre-exposure.

A person with acute HB can become a chronic HB carrier and remain infectious. Chronic infection may lead to serious liver disease.

Priority populations to receive the vaccine include:

• Children <7 years old whose families have immigrated from countries of high prevalence for HBV
  and who may be exposed to HBV carriers through their extended families (3 doses)
• Household and sexual contacts of chronic carriers and acute cases (3 doses)
• History of a sexually transmitted disease (3 doses)
• Infants born to HBV-positive carrier mothers:
  • premature infants weighing <2,000 grams at birth (4 doses)
  • premature infants weighing ≥2,000 grams at birth and full/post term infants (3 doses) • Intravenous drug use (3 doses)
• Liver disease (chronic), including hepatitis C (3 doses)
• Awaiting liver transplants (2nd and 3rd doses only)
• Men who have sex with men (3 doses)
• Multiple sex partners (3 doses)
• Needle stick injuries in a non-health care setting (3 doses)
• On renal dialysis or those with diseases requiring frequent receipt of blood products
  (e.g., haemophilia) (2nd and 3rd doses only)

For more information:

canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-hepatitis-b-vaccine.html